[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin 2020;70:7-30.

[2] Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:849-61.

[3] Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung Cancer - Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin 2017;67:138-55.

[4] Vilmann P, Clemensten PF, Colella S; Siemsen M, De Leyn P, Dumonceau JM, et al. Combined Endobronchial and Oesophageal Endosonography for the Diagnosis and Staging of Lung Cancer. Eur Respir J 2015;46:40-60.

[5] Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced NonSmall-Cell Lung Cancer. J Clin Oncol 2010;28:2181-90.

[6] Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:1919-29.

[7] Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy Plus Chemotherapy With or Without Surgical Resection for Stage III Non-Small-Cell Lung Cancer: A Phase III Randomised Controlled Trial. Lancet 2009;374:379-86.

[8] Delgado Bolton RC, Calapaquí-Terán AK, Giammarile F, Rubello D. Role of 18 F-FDG PET/CT in Establishing New Clinical and Therapeutic Modalities in Lung Cancer. A Short Review. Rev Esp Med Nucl Imagen Mol 2019;38:229-33.

[9] Fernández Pérez G, Sánchez Escribano R, García Vicente AM, Luna Alcalá A, Ceballos Viro J, Delgado Bolton RC, et al. SEOM-SERAM-SEMNIM Guidelines on the Use of Functional and Molecular Imaging Techniques in Advanced Non-Small-Cell Lung Cancer. Radiologia 2018;60:332-46.

[10] Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of Positron Emission Tomography in the Preoperative Assessment of Patients with Suspected Non-Small-Cell Lung Cancer: The PLUS Multicentre Randomised Trial. Lancet 2002;359:1388-93.

[11] Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-Small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial. J Thorac Oncol 2011;6:1367-72.

[12] Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, et al. Diagnostic Value of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for the Detection of Metastases in Non-Small-Cell Lung Cancer Patients. Int J Cancer 2013;132:E37-47.

[13] Zhao L, He ZY, Zhong XN, Cui ML. (18)FDG-PET/CT for Detection of Mediastinal Nodal Metastasis in NonSmall Cell Lung Cancer: A Meta-analysis. Surg Oncol 2012;21:230-6.

[14] Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I Figuls M. PET-CT for Assessing Mediastinal Lymph Node Involvement in Patients with Suspected Resectable Non-Small Cell Lung Cancer. Cochrane Database Syst Rev 2014;2014:CD009519.

[15] Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, et al. PET/CT Imaging for Target Volume Delineation in Curative Intent Radiotherapy of NonSmall Cell Lung Cancer: IAEA Consensus Report 2014. Radiother Oncol 2015;116:27-34.

[16] Hollingdale AE, Roques TW, Curtin J, Martin WM, Horan G, Barrett A. Multidisciplinary Collaborative Gross Tumour Volume Definition for Lung Cancer Radiotherapy: A Prospective Study. Cancer Imaging 2011;11:202-8.

[17] Hallqvist A, Alverbratt C, Strandell A, Samuelsson O, Björkander E, Liljegren A, et al. Positron Emission Tomography and Computed Tomographic Imaging (PET/ CT) for Dose Planning Purposes of Thoracic Radiation with Curative Intent in Lung Cancer Patients: A Systematic Review and Meta-analysis. Radiother Oncol 2017;123:71-7.

[18] Zhang C, Liu J, Tong J, Sun X, Song S, Huang G. 18F-FDGPET Evaluation of Pathological Tumour Response to Neoadjuvant Therapy in Patients with NSCLC. Nucl Med Commun 2013;34:71-7.

[19] He YQ, Gong HL, Deng YF, Li WM. Diagnostic Efficacy of PET and PET/CT for Recurrent Lung Cancer: A Metaanalysis. Acta Radiol 2014;55:309-17.

[20] Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and Locally Advanced NonSmall-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Followup. Ann Oncol 2017;28:iv1-21.

[21] Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C, Deschepper E, Dekkers OM, et al. Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer: A Randomized Trial. JAMA 2010;304:2245-52.

[22] Sehgal IS, Dhooria S, Aggarwal AN, Behera D, Agarwal R. Endosonography Versus Mediastinoscopy in Mediastinal Staging of Lung Cancer: Systematic Review and Metaanalysis. Ann Thorac Surg 2016;102:1747-55.

[23] Um SW, Kim HK, Jung SH, Han J, Lee KJ, Park HY, et al. Endobronchial Ultrasound Versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer. J Thorac Oncol 2015;10:331-7.

[24] Zhang R, Ying K, Shi L, Zhang L, Zhou L. Combined Endobronchial and Endoscopic Ultrasound-Guided Fine Needle Aspiration for Mediastinal Lymph Node Staging of Lung Cancer: A Meta-analysis. Eur J Cancer 2013;49: 1860-7.

[25] Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for Staging NonSmall Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2013;143:e211S-50.

[26] Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M, et al. A Prospective Controlled Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Compared with Mediastinoscopy for Mediastinal Lymph Node Staging of Lung Cancer. J Thorac Cardiovasc Surg 2011;142:1393-400.

[27] Liberman M, Sampalis J, Duranceau A, Thiffault V, Hadjeres R, Ferraro P. Endosonographic Mediastinal Lymph Node Staging of Lung Cancer. Chest 2014;146: 389-97.

[28] Korevaar DA, Crombag LM, Cohen JF, Spijker R, Bossuyt PM, Annema JT. Added Value of Combined Endobronchial and Oesophageal Endosonography for Mediastinal Nodal Staging in Lung Cancer: A Systematic Review and Meta-analysis. Lancet Respir Med 2016;4:960-8.

[29] Kang HJ, Hwangbo B, Lee GK, Nam BH, Lee HS, Kim MS, et al. EBUS-Centred Versus EUS-Centred Mediastinal Staging in Lung Cancer: A Randomised Controlled Trial. Thorax 2014;69:261-8.

[30] Crombag LM, Dooms C, Stigt JA, Tournoy KG, Schuurbiers OC, Ninaber MK, et al. Systematic and Combined Endosonographic Staging of Lung Cancer (SCORE Study). Eur Respir J 2019;53:1800800.

[31] Sanz-Santos J, Serra P, Torky M, Andreo F, Centeno C, Mendiluce L, et al. Systematic Compared with Targeted Staging with Endobronchial Ultrasound in Patients with Lung Cancer. Ann Thorac Surg 2018;106:398-403.

[32] Navani N, Nankivell M, Lawrence DR, Lock S, Makker H, Baldwin DR, et al. Lung Cancer Diagnosis and Staging with Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Compared with Conventional Approaches: An Open-label, Pragmatic, Randomised Controlled Trial. Lancet Respir Med 2015;3:282-9.

[33] Ge X, Guan W, Han F, Guo X, Jin Z. Comparison of Endobronchial Ultrasound-Guided Fine Needle Aspiration and Video-Assisted Mediastinoscopy for Mediastinal Staging of Lung Cancer. Lung 2015;193:757-66.

[34] Muthu V, Sehgal IS, Dhooria S, Aggarwal AN, Agarwal R. Efficacy of Endosonographic Procedures in Mediastinal Restaging of Lung Cancer after Neoadjuvant Therapy: A Systematic Review and Diagnostic Accuracy Metaanalysis. Chest 2018;154:99-109.

[35] Jiang L, Huang W, Liu J, Harris K, Yarmus L, Shao W, et al. Endosonography with Lymph Node Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled Data Analysis. J Thorac Cardiovasc Surg 2020;159:1099-108.

[36] Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, Molins López-Rodó L, Rodríguez Suárez PM, Sánchez de Cos Escuín J, et al. Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. Arch Bronconeumol 2016;52:378-88.

[37] Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, et al. Multidisciplinary Consensus Statement on the Clinical Management of Patients with Stage III Non-Small Cell Lung Cancer. Clin Transl Oncol 2020;22:21-36.

[38] De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS Guidelines for Preoperative Mediastinal Lymph Node Staging for Non-Small-Cell Lung Cancer. Eur J Cardiothorac Surg 2014;45:787-98.

[39] Obiols C, Call S, Rami-Porta R, Iglesias M, Saumench R, Serra-Mitjans M, et al. Extended Cervical Mediastinoscopy: Mature Results of a Clinical Protocol for Staging Bronchogenic Carcinoma of the Left Lung. Eur J Cardiothorac Surg 2012;41:1043-6.

[40] Call S, Obiols C, Rami-Porta R. Present Indications of Surgical Exploration of the Mediastinum. J Thorac Dis 2018;10:S2601-10.

[41] Rami-Porta R, Call S. Invasive Staging of Mediastinal Lymph Nodes: Mediastinoscopy and Remediastinoscopy. Thorac Surg Clin 2012;22:177-89.

[42] Zieliński M, Hauer L, Hauer J, Pankowski J, SzlubowskiA, Nabiałek T. Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) for Staging of Non-SmallCell Lung Cancer (NSCLC). Pneumonol Alergol Pol 2011;79:196-206.

[43] Turna A, Demirkaya A, Ozkul S, Oz B, Gurses A, Kaynak K. Video-Assisted Mediastinoscopic Lymphadenectomy is Associated with Better Survival than Mediastinoscopy in Patients with Resected Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg 2013;146:774-80.

[44] Marra A, Hillejan L, Fechner S, Stamatis G. Remediastinoscopy in Restaging of Lung Cancer after Induction Therapy. J Thorac Cardiovasc Surg 2008;135:843-9.

[45] Call S, Rami-Porta R, Obiols C, Serra-Mitjans M, GonzalezPont G, Bastús-Piulats R, et al. Repeat Mediastinoscopy in All its Indications: Experience with 96 Patients and 101 Procedures. Eur J Cardiothorac Surg 2011;39:1022-7.

[46] Jaklitsch MT, Gu L, Demmy T, Harpole DH, D’Amico TA, McKenna RJ, et al. Prospective Phase II Trial of Preresection Thoracoscopic Mediastinal Restaging after Neoadjuvant Therapy for IIIA (N2) Non-Small Cell Lung Cancer: Results of CALGB Protocol 39803. J Thorac Cardiovasc Surg 2013;146:9-16.

[47] NSCLC Meta-analysis Collaborative Group. Preoperative Chemotherapy for Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis of Individual Participant Data. Lancet 2014;383:1561-71.

[48] Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, et al. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Nonsmall-Cell Lung Cancer. J Clin Oncol 2010;28:3138-45.

[49] Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, et al. Surgery with or without Preoperative Paclitaxel and Carboplatin in Earlystage Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial. J Clin Oncol 2010;28:1843-9.

[50] Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, et al. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-SmallCell Lung Cancer. J Clin Oncol 2011;30:172-8.

[51] Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of Preoperative Chemoradiation in Addition to Preoperative Chemotherapy: A Randomised Trial in Stage III Non-Small-Cell Lung Cancer. Lancet Oncol 2008;9:636-48.

[52] Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction Chemoradiation in Stage IIIA/ N2 Non-Small-Cell Lung Cancer: A Phase 3 Randomised Trial. Lancet 2015;386:1049-56.

[53] Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, et al. Induction Chemoradiation is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer. Ann Thorac Surg 2012;93:1807-12.

[54] Chen Y, Peng X, Zhou Y, Xia K, Zhuang W. Comparing the Benefits of Chemoradiotherapy and Chemotherapy for Resectable Stage III A/N2 Non-Small Cell Lung Cancer: A Meta-analysis. World J Surg Oncol 2018;16:8.

[55] Krantz SB, Mitzman B, Lutfi W, Kuchta K, Wang CH, Howington JA, et al. Neoadjuvant Chemoradiation Shows no Survival Advantage to Chemotherapy Alone in Stage IIIA Patients. Ann Thorac Surg 2018;105:1008-16.

[56] Couñago F, Montemuiño S, Martin M, Taboada B, CalvoCrespo P, Samper-Ots MP, et al. Prognostic Factors in Neoadjuvant Treatment Followed by Surgery in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Multiinstitutional Study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin Transl Oncol 2019;21:735-44.

[57] Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA. Pulmonary Resection after High-Dose and Low-Dose Chest Irradiation. Ann Thorac Surg 2005;80:1224-30.

[58] Bharadwaj SC, Vallières E, Wilshire CL, Blitz M, Page B, Aye RW, et al. Higher Versus Standard Preoperative Radiation in the Trimodality Treatment of Stage IIIA Lung Cancer. Ann Thorac Surg 2015;100:207-13.

[59] Montemuiño S, Dios NR, Martín M, Taboada B, CalvoCrespo P, Samper-Ots MP, et al. High-Dose Neoadjuvant Chemoradiotherapy Versus Chemotherapy Alone Followed by Surgery in Potentially-Resectable Stage IIIA-N2 NSCLC. A Multi-institutional Retrospective Study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Rep Pract Oncol Radiother 2020;25:447-55.

[60] Tong S, Qin Z, Wan M, Zhang L, Cui Y, Yao Y. Induction Chemoradiotherapy Versus Induction Chemotherapy for Potentially Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis. J Thorac Dis 2018;10:2428-36.

[61] Xu YP, Li B, Xu XL, Mao WM. Is There a Survival Benefit in Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/ or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis. Medicine (Baltimore) 2015;94:e879.

[62] Van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. J Natl Cancer Inst 2007;99:442-50.

[63] Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients with Resectable Stage IIIA(N2) and Selected IIIB NonSmall-Cell Lung Cancer after Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol 2015;33:4194-201.

[64] Couñago F, Rodriguez de Dios N, Montemuiño S, JovéTeixidó J, Martin M, Calvo-Crespo P, et al. Neoadjuvant Treatment Followed by Surgery Versus Definitive Chemoradiation in Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Multi-Institutional Study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Lung Cancer 2018;118:119-27.

[65] Darling GE, Li F, Patsios D, Massey C, Wallis AG, Coate L, et al. Neoadjuvant Chemoradiation and Surgery Improves Survival Outcomes Compared with Definitive Chemoradiation in the Treatment of Stage IIIA N2 Non-Small-Cell Lung Cancer. Eur J Cardiothorac Surg 2015;48:684-90.

[66] Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, et al. Multidisciplinary Therapy of Stage IIIA Non-Small-Cell Lung Cancer: Long-term Outcome of Chemoradiation with or without Surgery. Cancer Control 2014;21:57-62.

[67] Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feldman L, et al. Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non-Small-Cell Lung Cancer. J Thorac Oncol 2013;8:915-22.

[68] Yang H, Yao F, Zhao Y, Zhao H. Clinical Outcomes of Surgery after Induction Treatment in Patients with Pathologically Proven N2-Positive Stage III Non-Small Cell Lung Cancer. J Thorac Dis 2015;7:1616-23.

[69] Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary Resection after Concurrent Chemotherapy and High Dose (60Gy) Radiation for Non-Small Cell Lung Cancer is Safe and May Provide Increased Survival. Eur J Cardiothorac Surg 2009;35:718-23.

[70] Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Raemdonck D, Nafteux P, et al. Surgical Multimodality Treatment for Baseline Respectable Stage IIIA-N2 Non-Small Cell Lung Cancer. Degree of Mediastinal Lymoh Node Involvement and Impact on Survival. Eur J Cardiothorac Surg 2009;36:433-9.

[71] Weder W, Collaud S, Eberhardt WE, Hillinger S, Welter S, Stahel R, et al. Pneumonectomy is a Valuable Treatment Option after Neoadjuvant Therapy for Stage III NonSmall-Cell Lung Cancer. J Thorac Cardiovasc Surg 2010;139:1424-30.

[72] Gaissert HA, Keum DY, Wright CD, Ancukiewicz M, Monroe E, Donahue DM, et al. POINT: Operative Risk of Pneumonectomy--Influence of Preoperative Induction Therapy. J Thorac Cardiovasc Surg 2009;138:289-94.

[73] Casiraghi M, Guarize J, Sandri A, Maisonneuve P, Brambilla D, Romano R, et al. Pneumonectomy in Stage IIIA-N2 NSCLC: Should it be Considered after Neoadjuvant Chemotherapy? Clin Lung Cancer 2019;20:97-106.

[74] Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, et al. Survival of Patients with Clinical Stage IIIA NonSmall Cell Lung Cancer after Induction Therapy: Age, Mediastinal Downstaging, and Extent of Pulmonary Resection as Independent Predictors. J Thorac Cardiovasc Surg 2011;141:48-58.

[75] Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, et al. Outcomes of Neoadjuvant Concurrent Chemoradiotherapy Followed by Surgery for Non-Small-Cell Lung Cancer with N2 Disease. Lung Cancer 2016;96:56-62.

[76] Stefani A, Alifano M, Bobbio A, Grigoroiu M, Jouni R, Magdeleinat P, et al. Which Patients Should be Operated on after Induction Chemotherapy for N2 Non-Small Cell Lung Cancer? Analysis of a 7-Year Experience in 175 Patients. J Thorac Cardiovasc Surg 2010;140:356-63.

[77] Cerfolio R, Maniscalco L, Bryan A. The Treatment of Patients with Stage IIIA Non-Small Cell Lung Cancer from N2 Disease: Who Returns to the Surgical Arena and who Survives. Ann Thorac Surg 2008;86:912-20.

[78] Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative Radiation Therapy is Associated with Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol 2015;33:2727-34.

[79] Postoperative Radiotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis of Individual Patient Data from Nine Randomised Controlled Trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-3.

[80] Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of Postoperative Radiation Therapy on Survival in Patients with Complete Resection and Stage I, II, or IIIA Non-Small-Cell Lung Cancer Treated with Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.

[81] Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, et al. Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:333-41.

[82] Mikell JL, Gillespie TW, Hall WA, Nickleach DC, Liu Y, Lipscomb J, et al. Postoperative Radiotherapy is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base. J Thorac Oncol 2015;10:462-71.

[83] Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, et al. Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated with Adjuvant Chemotherapy: A Review of the National Cancer Data Base. J Clin Oncol 2015;33:870-6.

[84] Corso CD, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non-Small-Cell Lung Cancer using the National Cancer Database. J Thorac Oncol 2015;10:148-55.

[85] Le Pechoux C, Pourel N, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, et al. LBA3_PR An International Randomized Trial, Comparing Post-operative Conformal Radiotherapy (PORT) to no PORT, in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC) and Mediastinal N2 Involvement: Primary End-point Analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann Oncol 2020;31:S1178.

[86] Curran WJ Jr., Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60.

[87] Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-Dose Radiation Improved Local Tumor Control and Overall Survival in Patients with Inoperable/Unresectable Non-Small-Cell Lung Cancer: Long-term Results of a Radiation Dose Escalation Study. Int J Radiat Oncol Biol Phys 2005;63:324-33.

[88] Rengan R, Rosenzweig KE, Venkatraman E, Koutcher LA, Fox JL, Nayak R, et al. Improved Local Control with Higher Doses of Radiation in Large-Volume Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2004;60:741-7.

[89] Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, et al. Higher Biologically Effective Dose of Radiotherapy is Associated with Improved Outcomes for Locally Advanced Non-Small Cell Lung Carcinoma Treated with Chemoradiation: An Analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012;82:425-34.

[90] Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-Dose Versus High-Dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin Plus Paclitaxel with or without Cetuximab for Patients with Stage IIIA or IIIB Non-SmallCell Lung Cancer (RTOG 0617): A Randomised, Two-byTwo Factorial Phase 3 Study. Lancet Oncol 2015;16:187-99.

[91] Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG OncologyRTOG 0617 Randomized Clinical Trial. J Clin Oncol 2017;35:56-62.

[92] Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, et al. Comparison of Concurrent Use of Thoracic Radiation with Either Carboplatin-Paclitaxel or CisplatinEtoposide for Patients with Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA Oncol 2017;3:1120-9.

[93] Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and Cisplatin Versus Paclitaxel and Carboplatin with Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Trial. Ann Oncol 2017;28:777-83.

[94] Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous NonSmall-Cell Lung Cancer. J Clin Oncol 2016;34:953-62.

[95] Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol 2019;30:863-70.

[96] Kelly K, Altorki NK, Eberhard WE, O’Brien ME, Spigel DR, Crino L, et al. Adjuvant Erlotinib Versus Placebo in Patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015;33:4007-14.

[97] Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy in Chinese Patients with Stage IIIA EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EVAN): A Randomised, OpenLabel, Phase 2 Trial. Lancet Respir Med 2018;6:863-73. [98] Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients with Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol 2019;37:97-104.

[99] Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-Mutant NSCLC (ADJUVANT/CTONG1104): A Randomised, Open-label, Phase 3 Study. Lancet Oncol 2018;19:139-48.

[100] Wu YL, Zhong W, Wang Q, Mao W, Xu ST, Wu L, et al. CTONG1104: Adjuvant Gefitinib Versus Chemotherapy for Resected N1-N2 NSCLC with EGFR Mutation--Final Overall Survival Analysis of the Randomized Phase III Trial 1 Analysis of the Randomized Phase III Trial. J Clin Oncol 2020;38:9005.

[101] Herbst RS, Tsuboi M, John T, Grohé C, Majem M, Goldman JW, et al. Osimertinib as Adjuvant Therapy in Patients (pts) with Stage IB–IIIA EGFR Mutation Positive (EGFRm) NSCLC after Complete Tumor Resection: ADAURA. J Clin Oncol 2020;38:LBA5.

[102] Franco F, Provencio M. Neoadjuvant Treatment with Tyrosine Kinase Inhibitors in Patients with Resectable NonSmall Cell Lung Cancer. J Thorac Dis 2019;11:4092-5.

[103] Xiong L, Li R, Sun J, Lou Y, Zhang W, Bai H, et al. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Oncologist 2019;24:157-64.

[104] Xiong L, Lou Y, Bai H, Li R, Xia J, Fang W, et al. Efficacy of Erlotinib as Neoadjuvant Regimen in EGFR-Mutant Locally Advanced Non-Small Cell Lung Cancer Patients. J Int Med Res 2020;48:300060519887275.

[105] Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, et al. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol 2019;37:2235-45.

[106] Sequist LV, Willers H, Lanuti M, Muzikansky A, Chen AB, Janne PA, et al. The ASCENT Trial: A Phase II Study of Neoadjuvant Afatinib, Chemoradiation and Surgery for Stage III EGFR Mutation-Positive NSCLC. J Clin Oncol 2018;36:8544.

[107] Xing L, Wu G, Wang L, Li JC, Wang J, Yuan Z, et al. A Multicenter, Randomized, Open-label, Phase II Trial of Erlotinib Versus Etoposide Plus Cisplatin with Concurrent Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Activating Mutation. J Clin Oncol 2017;35:8531.

[108] Cascone T, William WN, Weissferdt A, Lin HY, Leung CH, Carter BW, et al. Neoadjuvant Nivolumab (N) or Nivolumab Plus Ipilimumab (NI) for Resectable Non-Small Cell Lung Cancer (NSCLC): Clinical and Correlative Results from the NEOSTAR Study. J Clin Oncol 2019;37:8504.

[109] Melero I, Berraondo P, Rodríguez-Ruiz ME, Pérez-Gracia JL. Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. Cancer Discov 2016;6:1312-4.

[110] Blumenthal GM, Bunn PA Jr., Chaft JE, McCoach CE, Perez EA, Scagliotti GV, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 2018;13:1818-31.

[111] Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 2018;378:1976-86.

[112] Provencio M, Nadal E, Insa A, García-Campelo MR, CasalRubio J, Dómine M, et al. Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-label, Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol 2020;21:1413-22.

[113] Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. N Engl J Med 2004;350:351-60.

[114] Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.

[115] Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resected MAGE-A3-Positive Non-SmallCell Lung Cancer (MAGRIT): A Randomised, Doubleblind, Placebo-controlled, Phase 3 Trial. Lancet Oncol 2016;17:822-35.

[116] Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol 2020;15:288-93.

[117] Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018;379:2342-50.

[118] Girard N, Mornex F, Christoph D, Fietkau R, Filippi A, Field J, et al. 236 - PACIFIC-R: First Real-World Study of Patients with Unresectable, Stage III NSCLC Treated with Durvalumab after Chemoradiotherapy. Ann Oncol 2019;30:ii37.

[119] Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, et al. A Phase 2 Trial of Consolidation Pembrolizumab Following Concurrent Chemoradiation for Patients with Unresectable Stage III Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14-179. Cancer 2020;126:4353-61.

[120] Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, et al. Phase II Trial of Concurrent Atezolizumab with Chemoradiation for Unresectable NSCLC. J Thorac Oncol 2020;15:248-57.

[121] Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al. Safety Evaluation of Nivolumab Added Concurrently to Radiotherapy in a Standard First Line Chemo-Radiotherapy Regimen in Stage III Non-Small Cell Lung Cancer-The ETOP NICOLAS Trial. Lung Cancer 2019;133:83-7.

[122] Provencio-Pulla M, Nadal-Alforja E, Cobo M, Insa A, Rivas MC, Majem M, et al. Neoadjuvant Chemo/ Immunotherapy for the Treatment of Stages IIIA Resectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study-NADIM StudySLCG. J Clin Oncol 2018;36:8521.

[123] Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant Atezolizumab and Chemotherapy in Patients with Resectable Non-Small-Cell Lung Cancer: An Open-label, Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol 2020;21:786-95.

[124] Rothschild S, Zippelius A, Eboulet EI, Savic S, Betticher DC, Bettini A, et al. SAKK 16/14: Anti-PD-L1 Antibody Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC)--A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2020;38:9016.

[125] Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Irigoyen A, et al. Efficacy Evaluation of Concurrent Nivolumab Addition to a First-line, Concurrent ChemoRadiotherapy Regimen in Unresectable Locally Advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS Phase II Trial. Ann Oncol 2019;30:v591.